Showing results (41-50 of 52) with videos related to
Sort By:
Pageof 6
Journal of Neurology|April 29, 1998
Humoral immune response to p53 in malignant gliomaM Weller, A Bornemann, M Ständer, et al.Der Nervenarzt|April 1, 1997
[New developments in diagnosis and therapy of primary non-Hodgkin's lymphoma of the central nervous system]M Schabet, U Herrlinger, M Weller, et al.Journal of Neuro-Oncology|January 5, 1999
Intrathecal therapy of leptomeningeal CEM T-cell lymphoma in nude rats with anti-CD7 ricin toxin A chain immunotoxinU Herrlinger, H Schmidberger, R Buchholz, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 1, 1994
Malignant glioma: patterns of failure following individually tailored limited volume irradiationC F Hess, J C Schaaf, R D Kortmann, et al.Neurological Research|November 5, 1997
Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53M Weller, M Trepel, C Grimmel, et al.Journal of Neuroimmunology|March 1, 1991
The use of protease inhibitors in experimental allergic neuritisM Schabet, J N Whitaker, K Schott, et al.Journal of Neuro-Oncology|November 1, 1992
MR imaging of experimental meningeal melanomatosis in nude ratsJ Martos, D Petersen, U Klose, et al.Acta Neurologica Scandinavica|May 12, 1998
Clinical presentation and therapeutic outcome in 26 patients with primary CNS lymphomaU Herrlinger, M Schabet, M Clemens, et al.Journal of Neurology|June 3, 2000
A role for preirradiation PCV chemotherapy for oligodendroglial brain tumorsJ Streffer, M Schabet, M Bamberg, et al.Cancer|January 10, 2001
Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatmentU Herrlinger, M Schabet, W Brugger, et al.Pageof 6